Fig. 2From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofibanEfficacy of fondaparinux and enoxaparin in patients undergoing percutaneous coronary intervention. MACCE, including death from cardiovascular causes, non-fatal myocardial infarction and target vessel revascularization. P < 0.05 was considered to indicate statistical significanceBack to article page